Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma

Abstract For advanced non-squamous non-small cell lung cancer (NSCLC), although platinum/pemetrexed is known to result in a longer survival compared with other regimens, the outcome in the adjuvant setting is still unknown. In this study, the difference of the disease-free survival (DFS) between lun...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xiaoyu Zhai, Qiwen Zheng, Lu Yang, Yixiang Zhu, Junling Li, Yutao Liu, Ziping Wang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/105c6a8feff241cba53acd0189624629
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:105c6a8feff241cba53acd0189624629
record_format	dspace
spelling	oai:doaj.org-article:105c6a8feff241cba53acd01896246292021-12-02T15:06:03ZImpact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma10.1038/s41598-017-01347-62045-2322https://doaj.org/article/105c6a8feff241cba53acd01896246292017-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-01347-6https://doaj.org/toc/2045-2322Abstract For advanced non-squamous non-small cell lung cancer (NSCLC), although platinum/pemetrexed is known to result in a longer survival compared with other regimens, the outcome in the adjuvant setting is still unknown. In this study, the difference of the disease-free survival (DFS) between lung adenocarcinoma patients treated with platinum/pemetrexed and with other platinum-based doublets was concerned. A total of 389 radically resected lung adenocarcinoma patients received adjuvant chemotherapy with platinum/pemetrexed chemotherapy (Group A, n = 143) or other third generation platinum-based regimens (Group B, n = 246) were analyzed in terms of DFS. Propensity score matching (PSM) allowed generation of best matched pairs for the two categories. DFS was proved to be considerably better in pemetrexed doublets group (P = 0.0079); and platinum/pemetrexed was found to be associated with lower rates of several hematological and non-hematological adverse events (AEs), when compared with gemcitabine containing chemotherapy (leukopenia: RR 0.514, p = 0.001; neutropenia: RR 0.688, p = 0.002), or taxanes-doublets treatment (leukopenia: RR 0.685, p = 0.019; neutropenia: RR 0.805, p = 0.032). For patients with radically resected pulmonary adenocarcinoma, adjuvant chemotherapy with platinum/pemetrexed results in a better DFS and a less clinical toxicity in comparison with non-pemetrexed based doublets.Xiaoyu ZhaiQiwen ZhengLu YangYixiang ZhuJunling LiYutao LiuZiping WangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-9 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Xiaoyu Zhai Qiwen Zheng Lu Yang Yixiang Zhu Junling Li Yutao Liu Ziping Wang Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma
description	Abstract For advanced non-squamous non-small cell lung cancer (NSCLC), although platinum/pemetrexed is known to result in a longer survival compared with other regimens, the outcome in the adjuvant setting is still unknown. In this study, the difference of the disease-free survival (DFS) between lung adenocarcinoma patients treated with platinum/pemetrexed and with other platinum-based doublets was concerned. A total of 389 radically resected lung adenocarcinoma patients received adjuvant chemotherapy with platinum/pemetrexed chemotherapy (Group A, n = 143) or other third generation platinum-based regimens (Group B, n = 246) were analyzed in terms of DFS. Propensity score matching (PSM) allowed generation of best matched pairs for the two categories. DFS was proved to be considerably better in pemetrexed doublets group (P = 0.0079); and platinum/pemetrexed was found to be associated with lower rates of several hematological and non-hematological adverse events (AEs), when compared with gemcitabine containing chemotherapy (leukopenia: RR 0.514, p = 0.001; neutropenia: RR 0.688, p = 0.002), or taxanes-doublets treatment (leukopenia: RR 0.685, p = 0.019; neutropenia: RR 0.805, p = 0.032). For patients with radically resected pulmonary adenocarcinoma, adjuvant chemotherapy with platinum/pemetrexed results in a better DFS and a less clinical toxicity in comparison with non-pemetrexed based doublets.
format	article
author	Xiaoyu Zhai Qiwen Zheng Lu Yang Yixiang Zhu Junling Li Yutao Liu Ziping Wang
author_facet	Xiaoyu Zhai Qiwen Zheng Lu Yang Yixiang Zhu Junling Li Yutao Liu Ziping Wang
author_sort	Xiaoyu Zhai
title	Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma
title_short	Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma
title_full	Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma
title_fullStr	Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma
title_full_unstemmed	Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma
title_sort	impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/105c6a8feff241cba53acd0189624629
work_keys_str_mv	AT xiaoyuzhai impactofplatinumpemetrexedcombinationversusotherplatinumbasedregimensonadjuvantchemotherapyinresectedlungadenocarcinoma AT qiwenzheng impactofplatinumpemetrexedcombinationversusotherplatinumbasedregimensonadjuvantchemotherapyinresectedlungadenocarcinoma AT luyang impactofplatinumpemetrexedcombinationversusotherplatinumbasedregimensonadjuvantchemotherapyinresectedlungadenocarcinoma AT yixiangzhu impactofplatinumpemetrexedcombinationversusotherplatinumbasedregimensonadjuvantchemotherapyinresectedlungadenocarcinoma AT junlingli impactofplatinumpemetrexedcombinationversusotherplatinumbasedregimensonadjuvantchemotherapyinresectedlungadenocarcinoma AT yutaoliu impactofplatinumpemetrexedcombinationversusotherplatinumbasedregimensonadjuvantchemotherapyinresectedlungadenocarcinoma AT zipingwang impactofplatinumpemetrexedcombinationversusotherplatinumbasedregimensonadjuvantchemotherapyinresectedlungadenocarcinoma
_version_	1718388561023074304

Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma

Ejemplares similares